Cargando…

Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors

BACKGROUND: Response to immune checkpoint inhibitors (ICIs) is affected by multiple factors. This study aimed to explore whether sites of metastasis are associated with clinical outcomes of ICIs in advanced non-small-cell lung cancer (NSCLC) patients. METHODS: The data of NSCLC patients with high pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Jiayi, Gao, Ming, Gou, Qing, Xu, Chongrui, Yan, Honghong, Yang, Mingyi, Li, Jiakang, Yang, Xiaorong, Wei, Xuewu, Zhou, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481449/ https://www.ncbi.nlm.nih.gov/pubmed/35869859 http://dx.doi.org/10.1097/CM9.0000000000002217

Ejemplares similares

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis
por: Xu, Chongrui, et al.
Publicado: (2012)

Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era
por: Li, Jiakang, et al.
Publicado: (2022)

First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
por: Naito, Renato, et al.
Publicado: (2020)

Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis
por: Zhang, Qiuyi, et al.
Publicado: (2016)

The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2022)

Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Spillane, Susan, et al.
Publicado: (2020)

Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma
por: Sharma, Rohini, et al.
Publicado: (2021)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer
por: Huang, Zhe, et al.
Publicado: (2023)

18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors
por: Rivas, Alexia, et al.
Publicado: (2022)

Correction to: Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
Publicado: (2022)

Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
por: Gravara, Luigi Della, et al.
Publicado: (2020)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment
por: Wan, Mingyu, et al.
Publicado: (2022)

Are we over-treating with checkpoint inhibitors?
por: Danson, Sarah, et al.
Publicado: (2019)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
por: Ciciola, Paola, et al.
Publicado: (2020)

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%
por: Chen, Wei, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
por: Bamias, Aristotelis, et al.
Publicado: (2023)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors
por: Mahiat, Cédric, et al.
Publicado: (2023)

Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
por: Gao, Ling, et al.
Publicado: (2019)

First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis
por: Lin, Chang-Ting, et al.
Publicado: (2022)

Rational application of the first‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysis
por: Cao, Rui, et al.
Publicado: (2019)

Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study
por: Wang, Qi, et al.
Publicado: (2023)

Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy
por: Wu, Qinghua, et al.
Publicado: (2022)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
por: Huang, Zhangfeng, et al.
Publicado: (2020)

Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis
por: Lei, Qing, et al.
Publicado: (2022)

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level
por: Guo, Longhua, et al.
Publicado: (2019)

Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors
por: Melissaropoulos, Konstantinos, et al.
Publicado: (2020)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors
por: Boumaza, Xavier, et al.
Publicado: (2022)

Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
por: Li, Ying, et al.
Publicado: (2022)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy
por: Nasti, Tahseen H., et al.
Publicado: (2021)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy
por: Uehara, Yuji, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fal355v1r9cb25gmue4k6jpukl